PP-007 is a unique combination of a carbon monoxide releasing molecule and an oxygen transfer agent. The Food and Drug Administration (FDA) has granted Fast Track designation to PP-007 (PEGylated ...

The transaction includes $70m in cash and a $20m retained equity position for Nektar in a new Ampersand portfolio company.

Currently, it is unknown whether planned sequential delivery of active agents (for example, carboplatin for three to four cycles followed by three cycles of pegylated liposomal doxorubicin ...

After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar ...

Nektar Therapeutics (Nasdaq: NKTR), a global biotechnology company focused on the discovery and development of novel therapies to treat autoimmune disorders, today announced that it has entered into a ...

Just days after laying out $90 million to acquire Nektar Therapeutics’ Alabama manufacturing plant, Ampersand Capital ...

Among patients with polycythemia vera, the treatment pairing of Jakafi and Pegasys shows benefits with acceptable toxicity, ...

The transaction, subject to fulfillment of certain customary closing conditions, is expected to be finalized in December, ...

Nanoparticles have once again reached the spotlight, this time as a critical tool to combat the spread of covid-19. In this ...

Therapeutics announced that it has entered into a definitive agreement to sell its Huntsville, Alabama manufacturing facility and ...

Ed Arce, an analyst from H.C. Wainwright, maintained the Buy rating on Arbutus Biopharma (ABUS – Research Report). The associated price ...